ORLISTAT

Orlistat inhibits pancreatic and gastric lipases, reducing fat absorption for weight management. Benefits include modest weight loss and improved metabolic parameters. Side effects include oily stools, flatulence, fecal urgency, and fat‑soluble vitamin deficiency.

SKU: b423511b7359 Category: Tag:

Product Description


Mechanism of Action

ORLISTAT (ID 26962) shows a complex, multi‑pathway biochemical interaction profile involving modulation of enzyme‑regulated catalytic cycles, receptor‑level signalling networks, intracellular ion dynamics, mitochondrial respiratory control, redox‑balance adaptation, cytoskeletal organisation and transcription‑factor regulatory behaviour. Its physicochemical structure supports direct or indirect interaction with catalytic residues, allosteric pockets, membrane‑spanning receptors, signalling intermediates and structural proteins, enabling influence over second‑messenger pathways (Ca²⁺, cAMP, IP₃, DAG), phosphorylation kinetics, ROS generation and mitochondrial ATP‑synthesis efficiency.

Depending on concentration, exposure duration and biological substrate, ORLISTAT may shift metabolic routing, alter vesicular transport, influence chromatin accessibility, modify transcriptional clusters, or recalibrate mitochondrial stress‑response thresholds across diverse experimental models.

Benefits and Advantages

Common applications in research environments include:

  • High‑resolution receptor–ligand interaction analysis and molecular docking validation
  • Enzyme‑kinetic dissection and catalytic‑pathway reconstruction
  • Mitochondrial‑performance assays, redox‑stress modelling and ATP‑flux quantification
  • Multi‑omics integration: transcriptomics, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal‑dynamics studies involving actin, tubulin and membrane‑tension regulation
  • Apoptosis, autophagy, necroptosis, ferroptosis and stress‑response pathway mapping
  • SAR (structure–activity relationship) investigation and molecular‑optimisation workflows
  • Preclinical pharmacodynamic modelling and mechanistic dose‑response assays

Side Effects and Risks

Potential laboratory‑observed risks include:

  • ROS accumulation and oxidative‑stress imbalance
  • Mitochondrial hyperactivation or respiratory‑chain suppression
  • Disruption of Ca²⁺/Na⁺/K⁺ ionic homeostasis and ion‑channel behaviour
  • Unintended receptor cross‑activation or inhibitory interference
  • Cyto‑architectural destabilisation, membrane fragility or impaired trafficking
  • Dose‑dependent cytotoxicity and activation of apoptosis/autophagy signalling
  • Transcriptional and epigenetic instability under prolonged exposure
  • Inflammatory pathway activation (NF‑κB, MAPK, JNK)

Use exclusively under controlled laboratory conditions, following strict biosafety and handling protocols.

Datasheet


Molecular Formula

C29H53NO5

Molecular Weight

495.7 g/mol

CAS Number

96829-58-2

Storage Condition

Store at 25 °C (77 °F); excursions permitted to 15 to 30 °C (59 °F to 86 °F). Keep bottle tightly closed.

Solubility

Practically insoluble in water, freely soluble in chloroform, and very soluble in methanol and ethanol.

Purity

Purity information is available upon request (COA).

Synonym

orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Orlipastat

IUPAC/Chemical Name

[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate

InChl Key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

InChl Code

InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/3034010;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download